metricas
covid
Annals of Hepatology Most often read
Journal Information

Most often read

33628
Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group
Luis Antonio Diaz, Juan Pablo Arab, Francisco Idalsoaga, Javiera Perelli, Javier Vega, Melisa Dirchwolf, Javiera Carreño, Bárbara Samith, ... Mario G. Pessoa
Ann Hepatol. 2025;30:101903
33628
Full text access
11902
Treatment for hepatocellular carcinoma after immunotherapy
Landon L. Chan, Tsz Tung Kwong, Johnny C.W. Yau, Stephen L. Chan
Ann Hepatol. 2025;30:101781
11902
Full text access
9950
Is the liver resilient to the process of ageing?
Nirupama Chatterjee, Rishabh Sharma, Pratibha R Kale, Nirupma Trehanpati, Gayatri Ramakrishna
Ann Hepatol. 2025;30:101580
9950
Full text access
7267
Soft drink consumption and increased risk of nonalcoholic fatty liver disease: Results from the health workers cohort study
Edgar Denova-Gutiérrez, Berenice Rivera-Paredez, Amado D. Quezada-Sánchez, Brianda I. Armenta-Guirado, Paloma Muñoz-Aguirre, Yvonne N. Flores, Rafael Velázquez-Cruz, Jorge Salmerón
Ann Hepatol. 2025;30:101566
7267
Full text access
6945
Chronic hepatitis B virus persistence: Mechanisms, consequences and implications for achieving cure
Christopher Georgi, Simmone D’Souza, Carla Osiowy, Carla S. Coffin, Curtis L. Cooper
Ann Hepatol. 2025;30:101938
6945
Full text access
5776
Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045
Chengxia Kan, Kexin Zhang, Yuqun Wang, Xiaofei Zhang, Chang Liu, Yanhui Ma, Ningning Hou, Na Huang, ... Xiaodong Sun
Ann Hepatol. 2025;30:101898
5776
Full text access
5488
A comprehensive meta-analysis of stem cell therapy for liver failure: Assessing treatment efficacy and modality
Shenglong Lin, Haibing Gao, Huaxi Ma, Ziyuan Liao, Dongqing Zhang, Jinshui Pan, Yueyong Zhu
Ann Hepatol. 2025;30:101586
5488
Full text access
5396
Diagnostic performance of FibroTouch® in assessing hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: An Asian experience
Thanikan Sukaram, Soe Thiha Maung, Yuda Chongpison, Tassanan Jaihan, Chonlada Phathong, Roongruedee Chaiteerakij
Ann Hepatol. 2025;30:101753
5396
Full text access
5377
Association of sleep patterns and disorders with metabolic dysfunction-associated steatotic liver disease and liver fibrosis in contemporary American adults
Guannan Zong, Wangjia Mao, Ming Wen, Xiaoyun Cheng, Guanghui Liu
Ann Hepatol. 2025;30:101583
5377
Full text access
5169
Mechanisms and therapeutic targets of mitochondria in the progression of metabolic dysfunction-associated steatotic liver disease
Chenyang Mu, Sijie Wang, Zenghan Wang, Jian Tan, Haozan Yin, Yuefan Wang, Zhihui Dai, Dongyang Ding, Fu Yang
Ann Hepatol. 2025;30:101774
5169
Full text access
4975
cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B
Patricia Gita Naully, Marselina Irasonia Tan, Agustiningsih Agustiningsih, Caecilia Sukowati, Ernawati Arifin Giri-Rachman
Ann Hepatol. 2025;30:101533
4975
Full text access
4731
From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease
Mi Zhou, Jianyu Lv, Xinli Chen, Yujie Shi, Guanqun Chao, Shuo Zhang
Ann Hepatol. 2025;30:101777
4731
Full text access
4684
A global comparison of hepatitis B & C drug pricing
Leah Yao, Xiaohan Ying, Getan Malik, Catherine Tsai, Arun B. Jesudian, Robert S. Brown Jr., Stephen E. Congly
Ann Hepatol. 2025;30:101928
4684
Full text access
4220
Latin American association for the study of the liver (ALEH) guidance on preoperative care in liver transplantation: referral criteria, patient assessment, and waiting list management
Victoria Mainardi, Josefina Pages, Josemaría Menendez, Rodrigo Zapata, Luis Antonio Díaz, Sebastian Marciano, Fernando Cairo, Martin Padilla-Machaca, ... Alejandra Villamil
Ann Hepatol. 2025;30:101939
4220
Full text access
4150
Brain reserve in hepatic encephalopathy: Pathways of damage and preventive strategies through lifestyle and therapeutic interventions
Jacqueline Cordova-Gallardo, Andres Manuel Vargas-Beltran, Samantha Melanie Armendariz-Pineda, Jesus Ruiz-Manriquez, Javier Ampuero, Aldo Torre
Ann Hepatol. 2025;30:101740
4150
Full text access
4134
The burden of hepatic encephalopathy and the use of albumin as a potential treatment
Jasmohan S. Bajaj, Enrico Pompili, Paolo Caraceni
Ann Hepatol. 2025;30:101751
4134
Full text access
3595
A landscape of liver cirrhosis and transplantation in Mexico: Changing leading causes and transplant as response
Icela Palma-Lara, María Guadalupe Ortiz-López, José Bonilla-Delgado, Juanita Pérez-Escobar, Ricardo Godínez-Aguilar, Claudia Luévano-Contreras, Ana María Espinosa-García, Javier Pérez-Durán, ... Carmen Palacios-Reyes
Ann Hepatol. 2025;30:101562
3595
Full text access
3555
Latin American association for the study of the liver (ALEH) guidance on postoperative care after liver transplantation
Liana Codes, Rodrigo Zapata, Manuel Mendizabal, Alfeu de Medeiros Fleck Junior, Juan Carlos Restrepo, Leonardo de Lucca Schiavon, Luiz Marcelo Sá Malbouisson, Wellington Andraus, ... members of ALEH Special Interest Group on Liver Transplantation
Ann Hepatol. 2025;30:101899
3555
Full text access
3463
Clinical usefulness of an ultra-high-sensitivity hepatitis B surface antigen assay to determine the cessation of treatment for HBV reactivation
Takanori Suzuki, Akihiro Tamori, Kentaro Matsuura, Takako Inoue, Shigeru Kusumoto, Shinya Hagiwara, Haruka Sagi, Atsushi Kaneko, ... Yasuhito Tanaka
Ann Hepatol. 2025;30:101764
3463
Full text access
Article options
Tools